Tumor-derived CD4+CD25+ Tregs Inhibit the Maturation and Antigen-Presenting Function of Dendritic Cells

Du, Yong; Chen, Xin; Lin, Xiuqing; Wu, Wei; Huang, Zhiming

doi:10.7314/apjcp.2015.16.7.2665

Cited by 9 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was not possible to determine how Tregs and TGF-β interact with each other in the blood from the current results. However, previous results suggest that reduction of either Tregs or TGF-β may contribute to downregulating harmful tumor suppression, which may favor tumor progression (64)(65)(66)(67)(68). In conjunction, serum cytokine profiles suggested that antitumor immunity is enhanced at 2 weeks after CIK cell treatment.…”

Section: Discussionmentioning

confidence: 73%

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Previous studies have reported that regulatory T cells (Tregs), which are physiologically engaged in the maintenance of immunological self-tolerance, have a critical role in the regulation of the antitumor immune response. Targeting Tregs has the potential to augment cancer vaccine approaches. The current study therefore aimed to evaluate the role of cytokine-induced killer (CIK) cell infusion in modulating Tregs in patients with non-small cell lung cancer (NSCLC). A total of 15 patients with advanced NSCLC were treated by an infusion of CIK cells derived from autologous peripheral blood mononuclear cells (PBMCs). By using flow cytometry and liquid chip analysis, subsets of T cells and natural killer (NK) cells in peripheral blood, and plasma cytokine profiles in the treated patients, were analyzed at 2 and 4 weeks after CIK cell infusion. Cytotoxicity of PBMCs (n=15) and NK cells (n=6) isolated from NSCLC patients was evaluated before and after CIK cell therapy. Progression-free survival (PFS) and overall survival (OS) were also assessed. Analysis of the immune cell populations before and after treatment showed a significant increase in NK cells (P<0.05) concomitant with a significant decrease in Tregs (P<0.01) at 2 weeks post-infusion of CIK cells compared with the baseline. NK group 2D receptor (NKG2D) expression on NK cells was also significantly increased at 2 weeks post-infusion compared with the baseline (P<0.05). There was a positive correlation between NKG2D expression and the infusion number of CIK cells (P<0.05).

show abstract

Section: Discussionmentioning

confidence: 73%

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Wang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…However, a high CD4+/CD8+ ratio was not related to tumor cell dissemination in our study [73]. Regulatory CD4+ T cells can prevent the differentiation and expansion of cytotoxic T cells as well as DC maturation [74–76] and therefore prevent tumor elimination. The initiation of the pre-metastatic niche, e.g.…”

Section: Discussionmentioning

confidence: 80%

Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer

et al. 2019

View full text Add to dashboard Cite

BackgroundTumor-infiltrating lymphocytes (TILs) are described as an important immune modulator in the tumor microenvironment and are associated with breast cancer (BC) outcome. The spatial analysis of TILs and TIL subtype distribution at the invasive tumor front (ITF) and the tumor center (TC) might provide further insights into tumor progression.MethodsWe analyzed core biopsies from 87 pre-therapeutic BC patients for total TILs and the following subtypes: CD3+, CD4+, CD8+, CD20+ and CD68+ cells in correlation to clinicopathological parameters and disseminated tumor cells (DTCs) in the bone marrow.ResultsTILs and TIL subtypes showed significantly different spatial distribution among both tumor areas. TILs, especially CD3+ T cells were associated with the tumor status and tumor grading. BC patients responding to neoadjuvant chemotherapy had significantly more TILs and CD3+ T cells at the TC. The presence of DTCs after NACT was related to CD4+ infiltration at the TC.ConclusionThe dissimilar spatial association of TILs and TIL subtypes with clinicopathological parameters, NACT response and minimal residual disease underlines the necessity of detailed TIL analysis for a better understanding of immune modulatory processes.Electronic supplementary materialThe online version of this article (10.1186/s12885-019-5320-2) contains supplementary material, which is available to authorized users.

show abstract

“…Tregs can suppress effector T-cell differentiation and proliferation by direct contact inhibition or anti-inflammatory cytokine secretion. Moreover, Tregs was shown can diminish the upregulation of costimulatory molecule on splenic DCs 98 . Tregs also participate in the pathogenesis of H. pylori -induced chronic gastritis and many studies report increased numbers of CD4 + CD25 + Foxp3 + Tregs in the gastric mucosa of patients with H. pylori infections 99 , 100 .…”

Section: H Pylori Infection Induces Immunosuppressive Tregsmentioning

confidence: 99%

Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract

Yu¹,

Zhu²,

Li³

et al. 2018

Cell Death Dis

View full text Add to dashboard Cite

Helicobacter pylori has coexisted with humans for approximately 60,000 years and greater than 50% of the global population is infected with H. pylori. H. pylori was successfully cultured in vitro in 1983 and studies of H. pylori have achieved substantial advances over the last 35 years. Since then, H. pylori has been characterized as the primary pathogenic factor for chronic gastritis, peptic ulcer, and gastric malignancy. Numerous patients have received H. pylori eradication treatment, but only 1–2% of H. pylori-infected individuals ultimately develop gastric cancer. Recently, numerous epidemiological and basic experimental studies suggested a role for chronic H. pylori infection in protecting against inflammatory bowel disease (IBD) by inducing systematic immune tolerance and suppressing inflammatory responses. Here we summarize the current research progress on the association between H. pylori and IBD, and further describe the detailed molecular mechanism underlying H. pylori-induced dendritic cells (DCs) with the tolerogenic phenotype and immunosuppressive regulatory T cells (Tregs). Based on the potential protective role of H. pylori infection on IBD, we suggest that the interaction between H. pylori and the host is complicated, and H. pylori eradication treatment should be administered with caution, especially for children and young adults.

show abstract

Tumor-derived CD4+CD25+ Tregs Inhibit the Maturation and Antigen-Presenting Function of Dendritic Cells

Cited by 9 publications

References 20 publications

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Cytokine-induced killer cell therapy for modulating regulatory T cells in patients with non-small cell lung cancer

Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer

Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract

Contact Info

Product

Resources

About